Invention Grant
- Patent Title: Kanamycin antisense nucleic acid for the treatment of cancer
- Patent Title (中): 卡那霉素反义核酸用于治疗癌症
-
Application No.: US13258173Application Date: 2010-03-26
-
Publication No.: US09029135B2Publication Date: 2015-05-12
- Inventor: Rose Ann Padua , Christine Chomienne
- Applicant: Rose Ann Padua , Christine Chomienne
- Applicant Address: FR Paris FR Paris
- Assignee: Institut National de la Sante et de la Recherche Medicale (Inserm),Universite Paris Diderot-Paris 7
- Current Assignee: Institut National de la Sante et de la Recherche Medicale (Inserm),Universite Paris Diderot-Paris 7
- Current Assignee Address: FR Paris FR Paris
- Agency: McDermott Will & Emery LLP
- Priority: EP09290224 20090327
- International Application: PCT/EP2010/054039 WO 20100326
- International Announcement: WO2010/109016 WO 20100930
- Main IPC: C12N15/00
- IPC: C12N15/00 ; C12N15/11 ; A01N31/04 ; A61K39/39 ; C12N15/113 ; A61K39/00
Abstract:
The invention relates to a nucleic acid comprising a sequence complementary to a fragment of the sequence coding for the kanamycin resistance protein. This nucleic acid is useful as a DNA vaccine adjuvant, and can be used e.g. for treating cancer, for example in combination with a non-immunosuppressive inducer of tumor cell apoptosis such as all-trans retinoic acid (ATRA).
Public/Granted literature
- US20120076828A1 KANAMYCIN ANTISENSE NUCLEIC ACID FOR THE TREATMENT OF CANCER Public/Granted day:2012-03-29
Information query
IPC分类:
